VFA
DNLI icon

Valeo Financial Advisors’s Denali Therapeutics DNLI Stock Holding History

Valeo Financial Advisors’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-397
Closed -$10K – 1726
2020
Q2 		$10K Hold
397
– – ﹤0.01% 1277
2020
Q1 		$7K Buy
+397
New +$8.28K ﹤0.01% 1197

Other funds holding DNLI

CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Valeo Financial Advisors's DNLI Position: Q3 2020 in Review

Valeo Financial Advisors sold out of Denali Therapeutics (DNLI) in Q3 2020, closing a stake of 397 shares — an estimated $10K sold.

Valeo Financial Advisors first reported a position in DNLI in Q1 2020 and held it in 2 quarters. The position peaked at $10K in Q2 2020. 170 funds tracked by Wall St. Rank hold DNLI as of Q3 2020.

  • Valeo Financial Advisors reported no remaining Denali Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Valeo Financial Advisors sold 397 Denali Therapeutics shares in Q3 2020, an estimated $10K.
  • Valeo Financial Advisors first reported a position in Denali Therapeutics in Q1 2020 and held it in 2 quarters.
  • Valeo Financial Advisors's Denali Therapeutics position peaked at $10K in Q2 2020.
  • 170 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2020.

Based on Valeo Financial Advisors's 13F filing for Q3 2020, filed 28 Oct 2020.